
Opinion|Videos|August 23, 2024
Risk Stratification in Prostate Cancer Patients
Medical oncologists explore risk stratification strategies for newly diagnosed patients with prostate cancer, emphasizing the significant role of the Gleason score in diagnosis and prognosis.
Advertisement
Episodes in this series

Video content above is prompted by the following question:
- How do you approach risk stratification in prostate cancer patients, specifically in those newly diagnosed? (Brian Richardson, MD)
- Do you rely on the Gleason score, specific biomarkers, or a combination?
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
Mark Tyson, MD shares promising BOND-003 results in papillary NMIBC
2
CORE-008: Cretostimogene achieves high CR rate in high-risk NMIBC
3
Gemcitabine intravesical system delivers high 12-month DFS in papillary-only NMIBC
4
Choosing salvage therapy after prostate cancer focal ablation
5






















